{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:11Z","timestamp":1791474731137,"version":"4.3.4"},"reference-count":14,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies for ATC are emerging due to advances in molecular profiling of these tumors. Entrectinib is a potent oral selective inhibitor of neutrotrophic tropomyosin receptor kinase (\n                      <jats:italic>NTRK<\/jats:italic>\n                      ),\n                      <jats:italic>ROS1<\/jats:italic>\n                      , and anaplastic lymphoma kinase fusions. The experience regarding ATC and other thyroid carcinomas, particularly in the neoadjuvant setting, is minimal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      We present a case of a 51-year-old female patient presenting with a bulky mass of the left thyroid lobe measuring 100 \u00d7 108 \u00d7 80 mm that was considered surgically unresectable. While waiting for next-generation sequence (NGS) profiling, lenvatinib was initiated. There was an initial clinical and imagiologic response; however, progression occurred after 12 weeks, and at this time NGS identified an\n                      <jats:italic>ETV6-NTRK3<\/jats:italic>\n                      fusion and entrectinib was started. After 12 weeks, tumor diameters reduced to a minimum of 68\u00d760\u00d749 mm, and the patient underwent total thyroidectomy plus central lymphadenectomy. Histological diagnosis confirmed an ATC (pT4a R2 N1a). Adjuvant radiotherapy (RT) (60 Grays) with weekly paclitaxel (45 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was then administered followed by maintenance entrectinib 600 mg daily. Fluorodeoxyglucose positron emission tomography performed 3 months after completion of RT showed only non-specific uptake in the posterior wall of the hypopharynx and larynx, suggestive of inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We report the first case of an ATC with a dramatic response to neoadjuvant therapy with entrectinib, which enabled surgical resection of an\n                      <jats:italic>ab initio<\/jats:italic>\n                      unresectable tumor.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-22-0179","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T12:00:15Z","timestamp":1668513615000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":8,"title":["Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-669X","authenticated-orcid":true,"given":"In\u00eas","family":"Dam\u00e1sio","sequence":"first","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7119-5058","authenticated-orcid":true,"given":"Joana","family":"Sim\u00f5es-Pereira","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Donato","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"},{"name":"Nova Medical School, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Horta","sequence":"additional","affiliation":[{"name":"Radiology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branca Maria","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Molecular Pathobiology Research Unit (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rito","sequence":"additional","affiliation":[{"name":"Pathology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gomes","sequence":"additional","affiliation":[{"name":"Head and Neck Surgery Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriano","family":"Leite","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"},{"name":"Nova Medical School, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Kurume Medical Journal","first-page":"29","article-title":"Anaplastic thyroid carcinoma treated with lenvatinib","volume":"64","author":"Ohkubo","year":"2018","unstructured":"Ohkubo JITakahashi AIkezaki STakenaga FOhkubo YSuzuki H. Anaplastic thyroid carcinoma treated with lenvatinib. Kurume Medical Journal20186429\u201333. (https:\/\/doi.org\/10.2739\/kurumemedj.MS6406)"},{"key":"bib2","series-title":"Cancers","article-title":"Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options","volume":"11","author":"Sim\u00f5es-Pereira","year":"2019","unstructured":"Sim\u00f5es-Pereira JCapit\u00e3o RLimbert ELeite V. Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options. Cancers201911 1188. (https:\/\/doi.org\/10.3390\/cancers11081188)"},{"key":"bib3","series-title":"Modern Pathology","first-page":"2186","article-title":"Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)","volume":"33","author":"Chu","year":"2020","unstructured":"Chu YHDias-Santagata DFarahani AABoyraz BFaquin WCNos\u00e9 VSadow PM. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Modern Pathology2020332186\u20132197. (https:\/\/doi.org\/10.1038\/s41379-020-0574-4)"},{"key":"bib4","series-title":"Thyroid","first-page":"337","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","unstructured":"Bible KCKebebew EBrierley JBrito JPCabanillas MEClark TJJrDi Cristofano AFoote RGiordano TKasperbauer JAmerican Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid202131337\u2013386. (https:\/\/doi.org\/10.1089\/thy.2020.0944)"},{"key":"bib5","series-title":"Annals of Oncology","first-page":"325","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","unstructured":"Hong DSBauer TMLee JJDowlati ABrose MSFarago AFTaylor MShaw ATMontez SMeric-Bernstam FLarotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Annals of Oncology201930325\u2013331. (https:\/\/doi.org\/10.1093\/annonc\/mdy539)"},{"key":"bib6","series-title":"Lancet Oncology","first-page":"705","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","unstructured":"Laetsch TWDuBois SGMascarenhas LTurpin BFederman NAlbert CMNagasubramanian RDavis JLRudzinski EFeraco AMLarotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncology201819705\u2013714. (https:\/\/doi.org\/10.1016\/S1470-2045(1830119-0)"},{"key":"bib7","series-title":"Annals of Oncology","first-page":"S1026","article-title":"Waguespack Larotrectinib treatment of advanced TRK fusion thyroid cancer","volume":"31","author":"Cabanillas","year":"2020","unstructured":"Cabanillas MEDrilon AFarago AFBrose MSMcDermott RSohal DOh DAlmubarak MBauman JChu EWaguespack Larotrectinib treatment of advanced TRK fusion thyroid cancer. Annals of Oncology202031S1026\u2013S1033. (https:\/\/doi.org\/10.1016\/annonc\/annonc293)"},{"key":"bib8","series-title":"Lancet Oncology","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","unstructured":"Doebele RCDrilon APaz-Ares LSiena SShaw ATFarago AFBlakely CMSeto TCho BCTosi DEntrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncology202021271\u2013282. (https:\/\/doi.org\/10.1016\/S1470-2045(1930691-6)"},{"key":"bib9","series-title":"BMJ Case Reports","article-title":"Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe","volume":"13","author":"Barbaro","year":"2020","unstructured":"Barbaro DLapi PViacava PTorregrossa L. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Reports202013. (https:\/\/doi.org\/10.1136\/bcr-2020-236934)"},{"key":"bib10","series-title":"Modern Pathology","first-page":"38","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","unstructured":"Solomon JPLinkov IRosado AMullaney KRosen EYFrosina DJungbluth AAZehir ABenayed RDrilon ANTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology20203338\u201346. (https:\/\/doi.org\/10.1038\/s41379-019-0324-7)"},{"key":"bib11","series-title":"JCO Precision Oncology","first-page":"1","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2","author":"Okamura","year":"2018","unstructured":"Okamura RBoichard AKato SSicklick JKBazhenova LKurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precision Oncology201821\u201320. (https:\/\/doi.org\/10.1200\/PO.18.00183)"},{"key":"bib12","series-title":"Thyroid","first-page":"1505","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","unstructured":"Xu BFuchs TDogan SLanda IKatabi NFagin JATuttle RMSherman EGill AJGhossein R. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid2020301505\u20131517. (https:\/\/doi.org\/10.1089\/thy.2020.0086)"},{"key":"bib13","series-title":"JCO Precision Oncology","article-title":"Real-world experience of NTRK fusion-positive thyroid cancer","volume":"6","author":"Park","year":"2022","unstructured":"Park JCAshok ALiu CKang H. Real-world experience of NTRK fusion-positive thyroid cancer. JCO Precision Oncology20226 e2100442. (https:\/\/doi.org\/10.1200\/PO.21.00442)"},{"key":"bib14","series-title":"Thyroid","first-page":"923","article-title":"Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer","volume":"27","author":"I\u00f1iguez-Ariza","year":"2017","unstructured":"I\u00f1iguez-Ariza NMRyder MMHilger CRBible KC. Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid201727923\u2013927. (https:\/\/doi.org\/10.1089\/thy.2016.0627)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/12\/1\/ETJ-22-0179.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/1\/ETJ-22-0179.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/1\/ETJ-22-0179.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:40Z","timestamp":1784555500000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/2859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":14,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/etj-22-0179","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}